Combination treatment for glioblastoma cells with tumor necrosis factor-related apoptosis-inducing ligand and oncolytic adenovirus delta-24

Cancer Investigation

Volumn 31, Issue 9, 2013, Pages 630-638

  Tsamis, Konstantinos I ^a   Alexiou, George A ^a   Vartholomatos, Evrysthenis ^a   Kyritsis, Athanasios P ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adenovirus; Apoptosis; Caspase; Delta 24; Glioblastoma; TRAIL

Indexed keywords

CASPASE 8; DELTA 24; ONCOLYTIC ADENOVIRUS; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL DEATH; DRUG MECHANISM; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CASPASE 8; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; GLIOBLASTOMA; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECOMBINANT PROTEINS; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84887215097     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2013.849724     Document Type: Article

References (36)

1. Kyritsis AP, Levin VA. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol 2011;67(5):971-983.
2. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. Dec 1995;3(6):673-682.
3. Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther 2012;11(1):3-13.
4. Sheridan JP,Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277(5327):818-821.
5. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004;14(5):359-372.
6. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273(23):14363-14367.
7. BreckenridgeDG, XueD. Regulation ofmitochondrialmembrane permeabilization by BCL-2 family proteins and caspases. Curr Opin Cell Biol 2004;16(6):647-652.
8. Benedict CA, Ware CF. TRAIL: not just for tumors anymore? J Exp Med 2012;209(11):1903-1906.
9. SmythMJ, Takeda K,Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 2003;18(1):1-6.
10. Maksimovic-Ivanic D, Stosic-Grujicic S, Nicoletti F, Mijatovic S. Resistance to TRAIL and how to surmount it. Immunol Res 2012;52(1-2):157-168.
11. Kuijlen JM, Bremer E,Mooij JJ, den DunnenWF, Helfrich W. Review: on TRAIL formalignant glioma therapy? Neuropathol Appl Neurobiol 2010;36(3):168-182.
12. Kyritsis AP, Sioka C, Rao JS. Viruses, gene therapy and stem cells for the treatment of human glioma. Cancer Gene Ther 2009;16(10):741-752.
13. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. A mutant oncolytic adenovirus targeting the Rb pathway produces antiglioma effect in vivo. Oncogene 2000;19(1):2-12.
14. Jiang H, White EJ, Rios-Vicil CI, Xu J, Gomez-Manzano C, Fueyo J. Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J Virol 2011;85(10):4720-4729.
15. Mitlianga PG, Sioka C, Vartholomatos G, Goussia A, Polyzoidis K, Rao JS, Kyritsis AP. p53 enhances the Delta-24 conditionally replicative adenovirus anti-glioma effect. Oncol Rep 2006;15(1):149-153.
16. Lamfers ML, Idema S, Bosscher L, Heukelom S, Moeniralm S, van der Meulen-Muileman IH, Overmeer RM, van der Valk P, van Beusechem VW, Gerritsen WR, VandertopWP, Dirven CM. Differential effects of combined Ad5-delta 24RGD and radiation therapy in in vitro versus in vivomodels ofmalignant glioma. Clin Cancer Res 2007;13(24):7451-7458.
17. Jiang H, Gomez-Manzano C, Lang FF, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther 2009;9(5):422-427.
18. Rodrigues JR, Charris J, Camacho J, Barazarte A, Gamboa N, Nitzsche B, Hopfner M, Lein M, Jung K, Abramjuk C. N-Formyl-2-(5-nitrothiophen-2-yl) benzothiazole-6-carbohydrazide as a potential anti-tumour agent for prostate cancer in experimental studies. J Pharm Pharmacol 2013;65(3):411-422.
19. Atienza JM, Zhu J, Wang X, Xu X, Abassi Y. Dynamicmonitoring of cell adhesion and spreading on microelectronic sensor arrays. J Biomol Screen 2005;10(8):795-805.
20. Karsy M, GelbmanM, Shah P, Balumbu O, Moy F, Arslan E. Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. Folia Neuropathol 2012;50(4):301-321.
21. Bondy M, Wiencke J, Wrensch M, Kyritsis AP. Genetics of primary brain tumors: a review. J Neurooncol 1994;18(1):69-81.
22. Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene 2001;20(41):5789-5798.
23. Jiang H, Gomez-Manzano C, Alemany R, Medrano D, Alonso M, Bekele BN, Lin E, Conrad CC, Yung WK, Fueyo J. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 2005;7(1):48-56.
24. Villalonga-Planells R, Coll-Mulet L, Martinez-Soler F, Castano E, Acebes JJ, Gimenez-Bonafe P, Gil J, Tortosa A. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PloS One 2011;6(4): e18588.
25. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, Kaina B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007;26(2):186-197.
26. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002;21(15): 2283-2294.
27. Puduvalli VK, Sampath D, Bruner JM, Nangia J, Xu R, Kyritsis AP. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 2005;10(1):233-243.
28. Marini P, Schmid A, Jendrossek V, Faltin H, Daniel PT, Budach W, Belka C. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 2005;5:5.
29. Matthews GM, Newbold A, Johnstone RW. Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv Cancer Res 2012;116:165-197.
30. Kang YJ, Kim IY, Kim EH, Yoon MJ, Kim SU, Kwon TK, Choi KS. Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5. Exp Mol Med 2011;43(1):24-34.
31. Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW, Parney IF, Roa WH, Petruk KC. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 2001;61(3):1162-1170.
32. Jane EP, Premkumar DR, Pollack IF. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol Cancer Ther 2011;10(1):198-208.
33. Erba PA,Manfredi C, Lazzeri E,Minichilli F, Pauwels EK, Sbrana A, Strauss HW, Mariani G. Time course of paclitaxel-induced apoptosis in an experimental model of virus-induced breast cancer. J Nucl Med: official publication, Society of Nuclear Medicine 2010;51(5):775-781.
34. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Nat Cancer Inst 2003;95(9):652-660.
35. Li X, Mao Q, Wang D, Zhang W, Xia H. A fiber chimeric CRAd vector Ad5/11-D24 double-armed with TRAIL and arresten for enhanced glioblastoma therapy. Human Gene Ther 2012;23(6):589-596.
36. Wohlfahrt ME, Beard BC, Lieber A, Kiem HP. A capsidmodified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res 2007;67(18):8783-8790.